The Oncotype DX Breast Recurrence Score test provides a genomic-based, comprehensive, individualized risk assessment for early-stage invasive breast cancer in adjuvant and neoadjuvant settings. The test provides valuable information you can use to personalize a treatment plan specifically for each patient’s situation—including risk of distant recurrence, the benefit from chemotherapy and whether your patient can be treated effectively with hormonal therapy alone.1-6
The Breast Recurrence Score test is recognized as the standard of care. It’s included in clinical guidelines from organizations such as the American Society of Clinical Oncology (ASCO®), the National Comprehensive Cancer Network (NCCN®), the St. Gallen Consensus panel, the National Institute for Health Care Excellence (NICE), the European Society for Medical Oncology (ESMO) and the German Association of Gynecological Oncology (AGO), as well as in Czech clinical guidelines Modrá kniha.7-12*,24
The Breast Recurrence Score test is proven to predict the likely benefit of chemotherapy2,3 — as well as the risk of distant recurrence1,4— for patients who are newly diagnosed with early-stage invasive breast cancer. Eligible patients are diagnosed with early stage, ER+, HER2- breast cancer with either node-negative or node-positive disease. The test uses RT-PCR to measure the expression of 21 genes: 16 cancer-related genes and five reference genes - in a tumor sample after it has been removed by surgery or biopsy.
By testing every eligible patient after surgery, but before you discuss her treatment plan, you can make recommendations with increased insight and confidence.
The results are presented as a quantitative score, based on a continuous scale from 0-100. The score reflects individual tumor biology—the higher the score, the higher the risk of distant recurrence and the higher the likelihood of chemotherapy benefit are for that patient.2 The Breast Recurrence Score result can serve as a reference point for all members of the treatment team and can make discussing treatment options with your patients easier and more efficient.
The Breast Recurrence Score report also provides a quantitative ER score by RT-PCR to help assess the magnitude of hormonal therapy benefit13 and other supporting information (such as PR and HER2 scores). The test can provide insight into specific tumor biology, risk assessment and can inform treatment options.
Several large, independently run, international studies—including more than 63,000 patients15-23—found that the Breast Recurrence Score test is accurately associated with patient outcomes, including risk of distant recurrence and breast cancer survival. In addition, studies show that approximately 99% of node-negative patients with low Breast Recurrence Score results who were primarily treated using hormonal therapy alone (without chemotherapy) were distant recurrence-free after five years.14, 18
Whether patients have node-negative or node-positive breast cancer, the Breast Recurrence Score test is both prognostic and predictive – providing both important prognostic information about the estimated risk of distant recurrence and the likelihood of adjuvant chemotherapy benefit.1-6
For more information about the test Contact us.
*American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ASCO and NCCN do not endorse any product or therapy